1. Home
  2. VKTX vs LCID Comparison

VKTX vs LCID Comparison

Compare VKTX & LCID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • LCID
  • Stock Information
  • Founded
  • VKTX 2012
  • LCID 2007
  • Country
  • VKTX United States
  • LCID United States
  • Employees
  • VKTX N/A
  • LCID N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • LCID Auto Manufacturing
  • Sector
  • VKTX Health Care
  • LCID Consumer Discretionary
  • Exchange
  • VKTX Nasdaq
  • LCID Nasdaq
  • Market Cap
  • VKTX 4.7B
  • LCID 6.4B
  • IPO Year
  • VKTX 2015
  • LCID N/A
  • Fundamental
  • Price
  • VKTX $42.00
  • LCID $3.07
  • Analyst Decision
  • VKTX Strong Buy
  • LCID Hold
  • Analyst Count
  • VKTX 12
  • LCID 9
  • Target Price
  • VKTX $106.75
  • LCID $3.30
  • AVG Volume (30 Days)
  • VKTX 3.6M
  • LCID 109.1M
  • Earning Date
  • VKTX 02-05-2025
  • LCID 02-19-2025
  • Dividend Yield
  • VKTX N/A
  • LCID N/A
  • EPS Growth
  • VKTX N/A
  • LCID N/A
  • EPS
  • VKTX N/A
  • LCID N/A
  • Revenue
  • VKTX N/A
  • LCID $730,510,000.00
  • Revenue This Year
  • VKTX N/A
  • LCID $32.75
  • Revenue Next Year
  • VKTX N/A
  • LCID $84.89
  • P/E Ratio
  • VKTX N/A
  • LCID N/A
  • Revenue Growth
  • VKTX N/A
  • LCID 4.98
  • 52 Week Low
  • VKTX $17.23
  • LCID $1.93
  • 52 Week High
  • VKTX $99.41
  • LCID $4.43
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 35.23
  • LCID 62.28
  • Support Level
  • VKTX $39.09
  • LCID $2.49
  • Resistance Level
  • VKTX $43.48
  • LCID $3.52
  • Average True Range (ATR)
  • VKTX 2.15
  • LCID 0.27
  • MACD
  • VKTX 0.10
  • LCID 0.04
  • Stochastic Oscillator
  • VKTX 28.04
  • LCID 60.53

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About LCID Lucid Group Inc.

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.

Share on Social Networks: